Brown Advisory’s ANI Pharmaceuticals ANIP Stock Holding History

Brown Advisory’s Portfolio ANIP Stock Details ANIP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.71M	Sell	44,770 -2,480	-5%	-$199K	0.01%	611
2026 Q1	$3.63M	Sell	47,250 -1,174	-2%	-$91.6K	0.01%	584
2025 Q4	$3.82M	Buy	48,424 +33,340	+221%	+$2.89M	0.01%	579
2025 Q3	$1.38M	Sell	15,084 -1,895	-11%	-$155K	﹤0.01%	740
2025 Q2	$1.11M	Buy	16,979 +17	+0.1%	+$1.11K	﹤0.01%	786
2025 Q1	$1.14M	Hold	16,962	–	–	﹤0.01%	745
2024 Q4	$938K	Hold	16,962	–	–	﹤0.01%	818
2024 Q3	$1.01M	Hold	16,962	–	–	﹤0.01%	785
2024 Q2	$1.08M	Sell	16,962 -1,490	-8%	-$96.7K	﹤0.01%	754
2024 Q1	$1.28M	Hold	18,452	–	–	﹤0.01%	723
2023 Q4	$1.02M	Hold	18,452	–	–	﹤0.01%	760
2023 Q3	$1.07M	Sell	18,452 -1,600	-8%	-$92.3K	﹤0.01%	732
2023 Q2	$1.08M	Sell	20,052 -1,700	-8%	-$75.4K	﹤0.01%	735
2023 Q1	$864K	Hold	21,752	–	–	﹤0.01%	788
2022 Q4	$875K	Hold	21,752	–	–	﹤0.01%	782
2022 Q3	$699K	Hold	21,752	–	–	﹤0.01%	784
2022 Q2	$645K	Buy	21,752 +4,118	+23%	+$119K	﹤0.01%	790
2022 Q1	$496K	Buy	17,634 +3,333	+23%	+$124K	﹤0.01%	862
2021 Q4	$659K	Hold	14,301	–	–	﹤0.01%	813
2021 Q3	$469K	Hold	14,301	–	–	﹤0.01%	839
2021 Q2	$501K	Hold	14,301	–	–	﹤0.01%	842
2021 Q1	$517K	Sell	14,301 -180	-1%	-$5.64K	﹤0.01%	838
2020 Q4	$420K	Buy	14,481 +180	+1%	+$5.16K	﹤0.01%	814
2020 Q3	$403K	Buy	14,301 +1,991	+16%	+$59.3K	﹤0.01%	775
2020 Q2	$398K	Hold	12,310	–	–	﹤0.01%	767
2020 Q1	$502K	Hold	12,310	–	–	﹤0.01%	691
2019 Q4	$759K	Hold	12,310	–	–	﹤0.01%	690
2019 Q3	$897K	Buy	12,310 +1,200	+11%	+$89.8K	﹤0.01%	639
2019 Q2	$913K	Hold	11,110	–	–	﹤0.01%	649
2019 Q1	$784K	Buy	+11,110	New	+$654K	﹤0.01%	864

Other funds holding ANIP

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

GACM

Global Alpha Capital Management Montreal, Quebec, Canada $1.67B AUM 35.09% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Brown Advisory's ANIP Position: Q2 2026 in Review

Brown Advisory reduced its ANI Pharmaceuticals (ANIP) stake by 5.2% in Q2 2026, selling an estimated $199K and leaving 44,770 shares worth $3.71M. The position accounts for 0.01% of the portfolio, ranked #611.

Brown Advisory first reported a position in ANIP in Q1 2019 and has held it in 30 quarters since. The position peaked at $3.82M in Q4 2025. 308 funds tracked by Wall St. Rank hold ANIP as of Q2 2026.

Brown Advisory held 44,770 shares of ANI Pharmaceuticals worth $3.71M as of Q2 2026.
Brown Advisory sold 2,480 ANI Pharmaceuticals shares in Q2 2026, an estimated $199K.
ANI Pharmaceuticals made up 0.01% of Brown Advisory's portfolio in Q2 2026, its #611 holding.
Brown Advisory first reported a position in ANI Pharmaceuticals in Q1 2019 and has held it in 30 quarters since.
Brown Advisory's ANI Pharmaceuticals position peaked at $3.82M in Q4 2025.
308 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q2 2026.

Based on Brown Advisory's 13F filing for Q2 2026, filed 14 Aug 2026.